Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
Fourth quarter and full year 2017 net loss was
Selected Key Recent Highlights:
- Presented final results of STAR clinical trial data at the
Systemic Sclerosis World Congress . - Completed enrollment on investigator-initiated SCLERADEC-II trial.
- Presented bioequivalence trial results of ATI-0918 in ovarian cancer at AAPS.
Q4 and year-end 2017 Financial Performance
- Q4 2017 and year-end operating cash burn was
$4.2 million and$18.1 million , compared to$4.2 million and$19.5 million for the same periods in 2016, respectively. - Q4 2017 and year-end total revenues were
$1.5 million and$6.4 million , compared to$3.0 million and$11.4 million for the same periods in 2016, respectively. - Cash and debt principal balances at
December 31, 2017 were approximately$9.6 million and$13.0 million , respectively. - Q4 2017 adjusted net loss was
$4.3 million or$0.10 per share, compared to a net loss of$4.9 million or$0.24 per share for the same period in 2016. The adjusted net loss excludes a non-cash beneficial conversion feature related to the issuance of our Series B convertible preferred shares in the fourth quarter of 2017. Q4 2017 net loss allocable to common stockholders was$8.3 million , or$0.20 per share. - Fiscal 2017 adjusted net loss was
$21.0 million or$0.65 per share, compared to$22.0 million or$1.28 per share for the same period in 2016. The adjusted net loss excludes a$1.7 million non-cash charge for in-process research and development expense from the Azaya Therapeutics asset acquisition in the first quarter of 2017, as well as a$4.0 million non-cash beneficial conversion feature related to the issuance of our Series B convertible preferred shares in the fourth quarter of 2017. Fiscal 2017 net loss allocable to common stockholders was$26.7 million , or$0.82 per share.
“Manufacturing activities for our oncology drug, ATI-0918, a generic version of Caelyx®, are ongoing and on track for submitting an application to the
Selected Key Anticipated Milestones:
- Meet with U.S.
FDA to determine the next steps in the development pathway for Habeo™ Cell Therapy in patients with scleroderma-associated hand dysfunction. - Enroll first patient in the BARDA funded U.S. RELIEF burn clinical trial.
- Complete ATI-0918 manufacturing and regulatory activities required to prepare and file an application for EMA approval.
- Complete enrollment of the ADRESU clinical trial in
Japan . - Report of 24-week European SCLERADEC-II trial data for scleroderma hand dysfunction.
Management Conference Call Webcast
Cytori will host a management conference call at
About Cytori
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward-looking statements. Such statements, including, without limitation, statements regarding anticipated commercial launch of our Habeo™ therapy and ATI-0918 drug candidate (and timing thereof); completion of manufacturing activities necessary to submit an MAA to the EMA for our ATI-0918 drug candidate; our strategy for addressing our capital requirements through various activities, including operational efficiencies, revenue growth and accessing the capital markets; receipt of feedback from, and related discussions with, BARDA regarding our future contractual relationship with BARDA (and proposed BARDA funding of our thermal burn pilot trial); and our expected 2017 cash burn and reasons for the anticipated cash burn; are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, such as those associated with conduct and completion of the proposed thermal burn trial, as well as the Company’s anticipated submission of data to the EMA from the previously completed bioequivalence trial for ATI-0918. Specifically, the Company faces risks in the collection and results of the STAR scleroderma and RELIEF thermal burn trials, including enrollment risks, the risks that clinical data from one or more of these clinical trials will fail to demonstrate safety or efficacy of our product candidates, and risks that insufficiently positive clinical data will adversely affect government funding, regulatory approval pathways and commercial prospects for our cell therapy (e.g., Habeo), and nanomedicines product candidates. We also face risks that investigator-initiated trials using our Cytori Cell Therapy fail to fully enroll or otherwise are conducted in a manner that ultimately is injurious to our business. We also face the risk that we will be unable to successfully manufacture our ATI-0918 drug candidate in time to meet our projected timeline for submission of an MAA to the EMA, or at all. We also face risks regarding execution of our managed access program (MAP) strategy in
There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. Federal securities laws to do so.
| CYTORI THERAPEUTICS, INC. | ||||||||
| CONSOLIDATED CONDENSED BALANCE SHEETS | ||||||||
| (UNAUDITED) | ||||||||
| (in thousands, except share and par value data) | ||||||||
| As of December31, | ||||||||
| 2017 | 2016 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 9,550 | $ | 12,560 | ||||
| Accounts receivable, net of reserves of $167 in 2017 and 2016 | 145 | 1,242 | ||||||
| Restricted cash | 675 | 350 | ||||||
| Inventories, net | 3,183 | 3,725 | ||||||
| Other current assets | 1,311 | 870 | ||||||
| Total current assets | 14,864 | 18,747 | ||||||
| Property and equipment, net | 3,052 | 1,157 | ||||||
| Other assets | 2,570 | 2,336 | ||||||
| Intangibles, net | 7,207 | 8,447 | ||||||
| Goodwill | 3,922 | 3,922 | ||||||
| Total assets | $ | 31,615 | $ | 34,609 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 4,790 | $ | 5,872 | ||||
| Current portion of long-term obligations, net of discount | 13,624 | 6,629 | ||||||
| Total current liabilities | 18,414 | 12,501 | ||||||
| Deferred revenues | 94 | 97 | ||||||
| Long-term deferred rent and other | 107 | 17 | ||||||
| Long-term obligations, net of discount, less current portion | — | 11,008 | ||||||
| Total liabilities | 18,615 | 23,623 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 23,500 shares issued; 2,431 shares outstanding in 2017 and no shares outstanding in 2016 | — | — | ||||||
| Common stock, $0.001 par value; 75,000,000 shares authorized; 57,825,729 and 21,707,890 shares issued and outstanding in 2017 and 2016, respectively | 58 | 22 | ||||||
| Additional paid-in capital | 413,304 | 388,769 | ||||||
| Accumulated other comprehensive income | 1,387 | 1,258 | ||||||
| Accumulated deficit | (401,749 | ) | (379,063 | ) | ||||
| Total stockholders’ equity | 13,000 | 10,986 | ||||||
| Total liabilities and stockholders’ equity | $ | 31,615 | $ | 34,609 | ||||
| CYTORI THERAPEUTICS, INC. | ||||||||
| CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME | ||||||||
| (UNAUDITED) | ||||||||
| (in thousands, except share and per share data) | ||||||||
| For the Years Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Product revenues | $ | 2,689 | $ | 4,656 | ||||
| Cost of product revenues | 1,318 | 2,170 | ||||||
| Amortization of intangible assets | 1,225 | 545 | ||||||
| Gross profit | 146 | 1,941 | ||||||
| Development revenues: | ||||||||
| Government contracts and other | 3,722 | 6,724 | ||||||
| 3,722 | 6,724 | |||||||
| Operating expenses: | ||||||||
| Research and development | 11,678 | 16,197 | ||||||
| Sales and marketing | 3,593 | 3,611 | ||||||
| General and administrative | 7,594 | 8,563 | ||||||
| In process research and development acquired from Azaya | 1,686 | — | ||||||
| Total operating expenses | 24,551 | 28,371 | ||||||
| Operating loss | (20,683 | ) | (19,706 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 33 | 19 | ||||||
| Interest expense | (2,049 | ) | (2,592 | ) | ||||
| Other income, net | 13 | 233 | ||||||
| Total other expense | (2,003 | ) | (2,340 | ) | ||||
| Net loss | $ | (22,686 | ) | $ | (22,046 | ) | ||
| Beneficial conversion feature for convertible preferred stock | (3,977 | ) | — | |||||
| Net loss allocable to common stockholders | $ | (26,663 | ) | $ | (22,046 | ) | ||
| Basic and diluted net loss per share allocable to common stockholders | $ | (0.82 | ) | $ | (1.28 | ) | ||
| Basic and diluted weighted average shares used in calculating net loss per share allocable to common stockholders | 32,389,831 | 17,290,933 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (22,686 | ) | $ | (22,046 | ) | ||
| Other comprehensive income – foreign currency translation adjustments | 129 | 262 | ||||||
| Comprehensive loss | $ | (22,557 | ) | $ | (21,784 | ) | ||
| CYTORI THERAPEUTICS, INC. | ||||||||
| CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS | ||||||||
| (UNAUDITED) | ||||||||
| (in thousands) | ||||||||
| For the Years Ended December 31, |
||||||||
| 2017 | 2016 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (22,686 | ) | $ | (22,046 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 2,151 | 1,182 | ||||||
| Amortization of deferred financing costs and debt discount | 707 | 954 | ||||||
| In process research and development acquired from Azaya Therapeutics | 1,686 | — | ||||||
| Joint venture acquisition obligation accretion | — | 24 | ||||||
| Provision for expired inventory | 340 | 172 | ||||||
| Share-based compensation expense | 753 | 1,080 | ||||||
| Gain on asset disposal | (42 | ) | (127 | ) | ||||
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,129 | (179 | ) | |||||
| Inventories | 251 | 471 | ||||||
| Other current assets | (593 | ) | 633 | |||||
| Other assets | (94 | ) | (764 | ) | ||||
| Accounts payable and accrued expenses | (1,817 | ) | (673 | ) | ||||
| Deferred revenues | (3 | ) | (8 | ) | ||||
| Long-term deferred rent | 90 | (252 | ) | |||||
| Net cash used in operating activities | (18,128 | ) | (19,533 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (295 | ) | (67 | ) | ||||
| Proceeds from sale of assets | 113 | 131 | ||||||
| Purchase of long-lived assets as part of Azaya Therapeutics' acquisition | (1,201 | ) | — | |||||
| Change in restricted cash | (325 | ) | — | |||||
| Net cash (used in) provided by investing activities | (1,708 | ) | 64 | |||||
| Cash flows from financing activities: | ||||||||
| Principal payments on long-term obligations | (4,720 | ) | — | |||||
| Joint venture purchase payments | — | (1,774 | ) | |||||
| Proceeds from sale of common stock | 23,613 | 21,467 | ||||||
| Costs from sale of common stock | (2,078 | ) | (2,084 | ) | ||||
| Net cash provided by financing activities | 16,815 | 17,609 | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 11 | 82 | ||||||
| Net decrease in cash and cash equivalents | (3,010 | ) | (1,778 | ) | ||||
| Cash and cash equivalents at beginning of period | 12,560 | 14,338 | ||||||
| Cash and cash equivalents at end of period | $ | 9,550 | $ | 12,560 | ||||
| Cytori Therapeutics contact |
| Tiago Girao |
| +1.858.458.0900 |
| ir@cytori.com |
Source: